Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
ODAC Panel Okays Nolvadex to Reduce Breast Cancer Risk
October 1st 1998BETHESDA, Md--The Oncologic Drugs Advisory Committee (ODAC) has concluded that the Breast Cancer Prevention Trial (BCPT) was a risk-reduction and not a prevention trial. The panel specifically rejected the word prevention in recommending that the Food and Drug Administration approve Nolvadex (tam-oxifen citrate, Zeneca Pharmaceuticals) for "reducing a risk of breast cancer" in otherwise healthy women at high-risk of developing the disease. The drug is currently approved as adjuvant therapy for early and advanced breast cancer.
Evolving Role for Preoperative Chemo in Breast Cancer
October 1st 1998AMELIA ISLAND, Fla--Systemic chemotherapy has emerged as an integral part of the treatment of operable breast cancer. Now, researchers are investigating whether variations in the timing of chemotherapy may further influence patient outcomes.
Device Finds Breast Lesions by Measuring Electropotentials
October 1st 1998LONDON--A multicenter clinical study has shown that a new noninvasive diagnostic modality, which measures electropotentials at the skin surface in the region of a suspicious breast lesion, helps physicians discriminate benign lesions from breast cancer.
HercepTest Identifies Breast Cancer Tumors That Overexpress HER2
October 1st 1998COPENHAGEN, Denmark--Dako Corporation’s HercepTest was recommended unanimously for FDA approval by a joint committee of the Hematology and Pathology Devices Panel and Immunology Devices Panel, conditional on the company providing clear guidelines on how to conduct the test, so that laboratories can provide consistent results
Educational ‘Toolbox’ Helps Cancer Survivors
October 1st 1998SAN FRANCISCO--Susan Leigh, RN, a cancer survivor and oncology nurse, is telling a familiar story, but one that arouses her anger. Recently, a young woman with breast cancer went to the local library to research her disease. She was shocked to read in a medical text that her particular type of breast cancer had little hope of cure and was likely to be fatal in a few months.
Be a Survivor Breast Cancer Guides Available in Several Formats
October 1st 1998It’s a truism that we learn best when we get information from several senses," concludes a favorable review in the respected Journal of the National Cancer Institute of an interactive CD-ROM entitled "Be a Survivor: Your Interactive Guide to
Intensive Effort Required to Develop a Breast Cancer Risk Assessment Clinic
September 1st 1998ATLANTA--Cancer programs and hospitals wishing to expand their services to include genetic counseling and testing should be aware that the staff and resource needs are intense, Constance Roche, MSN, RN, CS, said at a conference sponsored by the National Consortium of Breast Centers. Ms. Roche and Kevin Hughes, MD, who were instrumental in establishing the Lahey Clinic Risk Assessment Program, Peabody, Massachusetts, offered advice on establishing and operating such a program.
Advice Offered for Daughters of Women With Breast Cancer
September 1st 1998NEW YORK--Caring for a mother with advanced breast cancer can be a lot to deal with for a daughter. She has the tricky task of reversing roles with her mother. She may have a family of her own to care for--and there is the fear that she is at risk for cancer herself.
Preventive Effects of Tamoxifen Vary With HER2 Level
September 1st 1998LOS ANGELES--Tamoxifen (Nol-vadex) may not prevent breast cancer recurrence in women whose tumors over-express the HER2 oncogene (also known as c-erbB-2), and such overexpression may be a predictor of responsiveness to chemotherapy, researchers said at the ASCO integrated symposium on HER2 in breast cancer.
Lymphatic Mapping in the Treatment of Breast Cancer
Developed initially for the treatment of malignant melanoma, lymphatic mapping and sentinel lymph node biopsy have recently been introduced into the treatment of early breast cancer. In breast cancer patients, harvested
Dyspnea Is a Common Symptom of Lung, Breast Cancer
August 31st 1998HOUSTON--More than half of the patients who present to M.D. Anderson Cancer Center’s emergency room have a complaint of dyspnea, Sandra Henke, RN, a thoracic oncology nurse at M.D. Anderson, said at the Center’s 2nd Annual Nursing Conference. "Even when there are other emergency symptoms, breathing difficulties are the most pronounced because they cause the most distress for the patient," Ms. Henke said.
UT Southwestern and Komen Foundation Offer Breast Care Fellowship
August 1st 1998The Center for Breast Care at UT Southwestern Medical Center in Dallas and the Susan G. Komen Breast Cancer Foundation have teamed up to offer a new 1-year fellowship for physicians interested in the multidisciplinary care of breast
European Tamoxifen Prevention Trials Contradict BCPT
August 1st 1998LONDON--Interim analyses of two randomized European trials of tamoxifen (Nolvadex) prophylaxis in healthy women have failed to show a significant reduction in the incidence of breast cancer, in contrast to the US Breast Cancer Prevention Trial (BCPT), which showed a 45% reduction with tamoxifen.
Komen Foundation Announces 1998 Postdoctoral Fellows
August 1st 1998DALLAS--The Susan G. Komen Breast Cancer Foundation has announced the recipients of its 1998 postdoctoral fellowship grants, which total more than $1 million. In addition to these 10 new first-year grant recipients, the Komen Foundation currently funds 21 previously awarded fellowships throughout the United States.
Avon Sponsors 3-Day Walk to Raise Funds for Breast Cancer
August 1st 1998LOS ANGELES--Avon’s Breast Cancer 3-Day is a new type of fundraising event--the first-ever multiday long distance walk. On October 23, 24, and 25, 1998, nearly 2,000 people in California will walk 50 to 60 miles (15 to 25 miles a day), beginning just south of Santa Barbara and ending just north of Malibu. Each participant has pledged to raise a minimum of $1,700 to support breast cancer awareness and education.
NSABP Researchers Report on the Tamoxifen Breast Cancer Prevention Trial
August 1st 1998Researchers from the Pittsburgh-based National Surgical Adjuvant Breast and Bowel Project (NSABP) presented data on the Breast Cancer Prevention Trial (BCPT) during a plenary session of the recent American Society of Clinical Oncology
ACS Offers Catalog of Hard-to-Find Products for Cancer Patients
August 1st 1998ATLANTA--The American Cancer Society is offering a "magalog," part magazine, part catalog, for women recovering from breast cancer and other cancers that involve treatment-related hair loss. Known as tlc (tender loving care), the nonprofit publication was created by Lana Leavitt Rosenfeld, an ACS volunteer.
NCCN Receives $1 Million Grant From Genentech
August 1st 1998PHILADELPHIA--The NCCN (National Comprehensive Cancer Network) has received a $1 million unrestricted grant from Genentech, Inc. The grant, provided over a 2-year period, will be used to support the development and expansion of the NCCN Oncology Outcomes Database with emphasis on breast cancer and non-Hodgkin’s lymphoma.
Oral Capecitabine in Taxol-Refractory Breast Cancer
August 1st 1998LOS ANGELES--For patients with refractory metastatic breast cancer, ideal therapy would offer palliation with ease of administration and limited side effects. The new agent capecitabine (Xeloda) can be taken orally at home, making it unique among currently available salvage regimens for metastatic breast cancer, Joanne L. Blum, MD, PhD, of Texas Oncology, Dallas, said at the 34th Annual Meeting of the American Society of Clinical Oncology (ASCO).
ODAC Gives Nod to Wider Taxotere Use
August 1st 1998WASHINGTON--The FDA’s On-cology Drugs Advisory Committee (ODAC) has recommended full approval of Rhône-Poulenc Rorer’s Taxotere (docetaxel) and a widening of the advanced breast cancer indication that received conditional approval in 1996, subject to completion of phase III trials.
Researchers Developing Less Toxic Therapy to Target Breast Cancer Cells
August 1st 1998University of California, San Francisco, researchers have received approval from the National Cancer Institute (NCI) to develop a less toxic breast cancer therapy that may also prove to be more efficient at directly targeting cancer cells.